Therasphere® and Systemic Therapy for Patients With Hepatocellular Carcinoma That is High-risk

The purpose of this research is to compare progression free survival between two available systemic therapies - immunotherapy and tyrosine kinase inhibitors - after Therasphere® (yttrium-90) treatment in adult patients with advanced hepatocellular carcinoma. The immunotherapy consists of a standard-of-care treatment with Atezolizumab and Bevacizumab. Treatment with tyrosine kinase inhibitors consists of standard-of-care Lenvatinib or Cabozantinib.

Trial Details

NCT ID
NCT05620771
Phase
PHASE2
Sponsor
Northwestern University
Status
RECRUITING
Cancer Type
Liver Cancer
Interventions
  • Y90 + Atezolizumab and Bevacizumab
  • Y90 + TKI
Locations (sample)
  • Chicago, Illinois, United States|41.85003,-87.65005
  • DeKalb, Illinois, United States|41.92947,-88.75036
  • Geneva, Illinois, United States|41.88753,-88.30535
  • Grayslake, Illinois, United States|42.34447,-88.04175
  • Lake Forest, Illinois, United States|42.25863,-87.84063

Key Eligibility Criteria

  • 1.1 Patients must have a diagnosis of hepatocellular carcinoma (HCC) confirmed by American Association for Study of Liver Diseases (AASLD) guidelin…
  • 1.2 Patients must have at least 1 lesion that is measurable using RECIST guidelines. NOTE: A previously irradiated lesion can be considered a targe…
  • 1.3 Patients may be treatment -naïve or have received any number of prior therapies. NOTE: Prior cancer targeted immunotherapy for any other cancer…
  • 1.4 Adults ≥18 years old of either gender are eligible.

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Liver Cancer Trials on Trialify →